MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural Mesothelioma
Diagnostics · 11.04.2026 · 16 (8) · 1142
DOI: 10.3390/diagnostics16081142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 11.04.2026. Verfasst von Berta Mosleh und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Medical University of Vienna, 1090 Vienna, Austria. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FWF Austrian Science Fund, “Initiative Krebsforschung” of the Medical University of Vienna, Austrian Science Fund.
Abstract (Originalsprache)
Background/Objective: The identification of novel non-invasive diagnostic and prognostic biomarkers is urgently needed in pleural mesothelioma (PM). While soluble mesothelin-related peptides (SMRP) are the most established circulating biomarker, their prognostic value is limited. A wide range of microRNAs (miRs) play diverse roles in regulating gene expression in PM. MiR-21 has been shown to be upregulated in mesothelioma tissue; nevertheless, the diagnostic and prognostic utility of miR-21 in the circulation and its association with survival in PM have not been extensively investigated to date. The objective of the current study was to evaluate miR-21 as a potential blood-based diagnostic and prognostic biomarker in PM.
Methods
Plasma samples from PM patients (n = 94) were collected at the time of diagnosis, prior to treatment. Sex- and age-matched healthy individuals (n = 30) served as controls. MiR-21 levels were measured using quantitative RT-PCR and normalized to miR-16, and potential correlations with clinicopathological data were analyzed. Serum SMRP levels were measured in matched patients (n = 84), and a direct comparative analysis of miR-21 and SMRP was conducted. In situ hybridization (ISH) was used to confirm the presence of miR-21 in tumor cells.
Results
Plasma miR-21 levels were significantly elevated in PM patients compared to healthy controls (p < 0.001), demonstrating good diagnostic performance (AUC 0.81). The localization of miR-21 in PM cells was confirmed by ISH. High miR-21 levels were associated with significantly shorter median overall survival (12.4 vs. 24.3 months, p < 0.001). Elevated SMRP levels were also associated with reduced survival (12.4 vs. 19.5 months, p = 0.032); however, SMRP did not retain independent prognostic significance in multivariable analysis. In contrast, high-circulating miR-21 was confirmed as an independent predictor for poor survival (HR 3.12, p < 0.001).
Conclusions
Our findings highlight that circulating miR-21 is a potential non-invasive biomarker with both diagnostic and independent prognostic value in pleural mesothelioma and outperforms SMRP in multivariable survival analysis. Further research is warranted to validate its role in the biology of this disease and to assess its correlation with outcome and treatment responses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Medical University of Vienna, 1090 Vienna, Austria.
- Center for Cancer Research, Medical University of Vienna, 1090 Vienna, Austria.
- Department of Thoracic Surgery, Karl Landsteiner Institute for Clinical and Translational Thoracic Surgery Research, Clinic Floridsdorf, 1210 Vienna, Austria.
- Sydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.
- Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
- Department of Thoracic Surgery, University Medicine Essen, University Duisburg-Essen, 45239 Essen, Germany.
ORCID-Profile: Berta Mosleh, Yawen Dong, Clemens Aigner, Balazs Hegedüs, Natalie Baldes, Servet Bölükbas, Balazs Dome, Mir Alireza Hoda, Michael Grusch
Förderung
- FWF Austrian Science Fund
- “Initiative Krebsforschung” of the Medical University of Vienna
- Austrian Science Fund
- City of Vienna Fund for Innovative Interdisciplinary Cancer Research
Zitieren
APA
Mosleh, B., Dong, Y., Lang, E., Klikovits, T., Sinn, K., Kao, S., Jakopovic, M., Aigner, C., Hegedüs, B., Baldes, N., Bölükbas, S., Dome, B., Hoda, M. A., Laszlo, V., Grusch, M., & Schelch, K. (2026). MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural Mesothelioma. Diagnostics, 16(8), 1142. https://doi.org/10.3390/diagnostics16081142
Vancouver
Mosleh B, Dong Y, Lang E, Klikovits T, Sinn K, Kao S, et al. MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural Mesothelioma. Diagnostics. 2026;16(8):1142. doi:10.3390/diagnostics16081142
BibTeX
@article{Mosleh2026,
author = {Mosleh, Berta and Dong, Yawen and Lang, Elisabeth and Klikovits, Thomas and Sinn, Katharina and Kao, Steven and Jakopovic, Marko and Aigner, Clemens and Hegedüs, Balazs and Baldes, Natalie and Bölükbas, Servet and Dome, Balazs and Hoda, Mir Alireza and Laszlo, Viktoria and Grusch, Michael and Schelch, Karin},
title = {MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural Mesothelioma},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {8},
pages = {1142},
doi = {10.3390/diagnostics16081142}
}
EUVIMED